Trial Profile
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) (MUK seven)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MUK Seven
- 24 May 2022 Planned End Date changed from 1 Mar 2023 to 1 Jun 2023.
- 24 May 2022 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2022.
- 10 Dec 2019 Results of Mukseven (NCT02406222) biomarker trial presented at the 61st Annual Meeting and Exposition of the American Society of Hematology